Asleh, Karama <br/><br/>
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.  [electronic resource] 

 -  International journal of cancer  05 2019 
 - 2578-2586 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.31969  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials, Phase III as Topic<br/>Deoxycytidine--analogs & derivatives<br/>Disease-Free Survival<br/>Docetaxel--therapeutic use<br/>Female<br/>Gene Expression Profiling--methods<br/>Humans<br/>Kaplan-Meier Estimate<br/>Nestin--metabolism<br/>Phosphoric Monoester Hydrolases--metabolism<br/>Prognosis<br/>Prospective Studies<br/>Randomized Controlled Trials as Topic<br/>Retrospective Studies<br/>Gemcitabine